BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 28057176)

  • 1. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
    Lee J; Kefford R; Carlino M
    Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
    Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single versus combination immunotherapy drug treatment in melanoma.
    Grimaldi AM; Marincola FM; Ascierto PA
    Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab use for the treatment of advanced melanoma.
    Specenier P
    Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in melanoma.
    Feld E; Mitchell TC
    Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Approaches to Immunotherapy in the Clinic.
    Agarwala SS
    Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives.
    Atkins MB; Larkin J
    J Natl Cancer Inst; 2016 Jun; 108(6):djv414. PubMed ID: 26839346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in advanced melanoma: a network meta-analysis.
    Pyo JS; Kang G
    Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.